MOLECULAR GENETIC ANALYSIS AND SPECTRUM OF MUTATIONS IN KATG, INHA, RPOB GENES CODING DRUG RESISTANCE TO ISONIAZID AND RIFAMPICIN IN THOSE SUFFERING FROM TB/HIV CO-INFECTION
https://doi.org/10.21292/2075-1230-2016-94-8-54-59
Abstract
About the Authors
T. Yu. SalinaRussian Federation
Doctor of Medical Sciences, Associate Professor at FPk and PPS tuberculosis Control Department,
112, B. Kazachya St., Saratov, 410012
S. A. Churkin
Russian Federation
Candidate of Medical Sciences, Head Doctor,
6, Nezhinskoye rd, Orenburg, 460041
T. I. Morozova
Russian Federation
Doctor of Medical Sciences, Professor, Head of FPK and PPS tuberculosis Control Department,
112, B. Kazachya St., Saratov, 410012
References
1. Babaeva I.Yu., Demikhova O.V., Kravchenko А.V. Problems of diagnostics and treatment of pulmonary disseminated tuberculosis in HIV patients. Tub. i Bolezni Legkikh, 2010, no. 8, pp. 57-61. (In Russ.)
2. Voronina E.N., Vikhrova M.А., Khrapov E.A. et al. Ser315- > Thr1 mutation in katG gene is the main cause of resistance to isoniazid in isolates of Mycobacterium tuberculosis prevalent in Novosibirsk and Kemerovo Regions. Molekulyarnaya Genetika, Mikrobiologiya i Virusologiya, 2004, no. 3, pp. 8-11. (In Russ.)
3. Korovkin V.S. Molecular basics of drug resistance in tuberculous mycobacteria. Med. Novosti. 2003, no. 9, pp. 8-13. (In Russ.)
4. Markelov Yu.M. Specifics of multiple drug resistant tuberculosis and priority actions to limit its transmission in Karelia. Vestnik Sovremennoy Klinicheskoy Meditsiny, 2011, vol. 4, no. 3, pp. 51-56. (In Russ.)
5. Rukovodstvo po legochnomu i vnelegochnomu tuberkulezu. [Manual on pulmonary and extrapulmonary tuberculosis]. Ed. by Yu.N. Levashov, Yu.M Repin, St. Petersburg, ELBI-Spb. Publ., 2008, 544 p.
6. Stepanshin Yu.G., Stepanshina V.N., Shemyakin I.G. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Antibiotiki i Khimioterapiya, 1999, no. 4, pp. 39-43. (In Russ.)
7. Frolova O.P., Polesskiy V.А., Kazenny А.B. Improvement of the procedure of anti-tuberculosis care provision to HIV patients in the Russian Federation. Zdravookhraneniye RF, 2013, no. 3, pp. 17-21. (In Russ.)
8. Frolova O.P., Polesskiy V.А., Novoselova O.А. et al. Tuberculosis inHIV patients as a national problem. Tub. i Bolezni Legkikh, 2013, no. 10, pp. 9-12. (In Russ.)
9. Нazbon M.N., Brimacombe M., Bobadilla del Valle M. et al. Population genetics study of isoniasid resistance mutations and evolution of multidrug–resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother., 2006, vol. 50, pp. 2640-2649.
10. Pym A. S., Domeneech P., Honore N. et al. Regulation of catalase-peroxidase (katG) expression, isoniasid sensitivity and virulence by furA of Mycobacterium tuberculosis. Molecular Microbiology, 2001, vol. 40, no. 4, pp. 879-889.
11. Saint-Joanis B., Souchon H., Wilming M. et al. Use ofside-directed mutaenesis to probe the structure, function and isoniasid activation of the catalase/peroxidase, kat G, from Mycobacterium tuberculosis. Biochem J., 1999, vol. 338, pp. 753-760.
12. Telenti A., Imboden P., Marchesi F. et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet, 1993, vol. 341, pp. 647-650.
13. Wilson T.M., de Lisle G.W., Collins D.M. Effect of inhA and katG on isoniasid resistance and virulence of Mycobacterium bovis. Molecular Microbiology, 1995, vol. 15, no. 6, pp. 1009-1015.
14. Wu X., Zhang J., Zhang Y. et al. Molecular mechanism of drug resistance in Mycobacterium tuberculosis clinical isolates. Clin. Med. J., 1999, vol. 112, no. 6, pp. 524-528.
15. Zhang Y., Yew W.W. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung. Dis., 2009, vol. 13, no. 11, pp. 1320-1330.
Review
For citations:
Salina T.Yu., Churkin S.A., Morozova T.I. MOLECULAR GENETIC ANALYSIS AND SPECTRUM OF MUTATIONS IN KATG, INHA, RPOB GENES CODING DRUG RESISTANCE TO ISONIAZID AND RIFAMPICIN IN THOSE SUFFERING FROM TB/HIV CO-INFECTION. Tuberculosis and Lung Diseases. 2016;94(8):54-59. (In Russ.) https://doi.org/10.21292/2075-1230-2016-94-8-54-59